Header

Multiple Myeloma Clinical Trials

Category:Adult
Status:Active

Displaying all 29 trials

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have not been approved in the combination for multiple myeloma or any other type of cancer. Bortezomib is curre...

Diagnosis: Multiple Myeloma

Phase: 3

Protocol Number: 10-106

Phase 2b Open-Label Single-Arm Study of Selinexor & Dexamethasone in Patients Exposed to Bortezomib, Carfilzomib, Lenalidomide and Pomalidomide

Patients with heavily pretreated, quad-exposed multiple myeloma (refractory to one PI and one IMiD) will receive selinexor 80 mg (45 mg/m2 BSA) plus low-dose dexamethasone (20 mg), both twice weekly.

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 15-291

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

This study is designed to compare progression-free survival (PFS) from randomization among patients randomized on the BMT CTN 1302 protocol, "Multicenter Phase II, Double-blind Placebo Control...

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 15-358

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

This research study is studying a targeted therapy as a possible treatment for relapsed or refractory Waldenstrom's Macroglobulinemia (WM). This study is using the study intervention ABT-199.

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 15-491

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidom...

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 15-475

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

The study is designed as a Phase II, multicenter trial of vaccination with Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide m...

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 16-113

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

This research study is studying a possible therapy as a possible treatment for the consequences of Multiple Myeloma with renal insufficiency.

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 15-571

A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma

This research study is evaluating Enterade, a supplement, as a possible treatment for the side effects caused by Stem Cell Transplant. The following interventions will be involved in this study: - ...

Diagnosis: Multiple Myeloma, Non-Hodgkin's Lymphoma

Phase: 2

Protocol Number: 16-329

Nivolumab + Lenalidomide + Dexamethasone In SMM

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myel...

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 16-242

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

The purpose of this study is to investigate the safety and efficacy of three different regimens of PAN (20 mg TIW, 20 mg BIW, and 10 mg TIW) in combination with s.c. BTZ and Dex and to provide expo...

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 16-199

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 16-313

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma

Diagnosis: Multiple Myeloma

Phase: 1 / 2

Protocol Number: 15-519

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

This is an open-label, multicenter study to confirm the safety and efficacy of durvalumab + daratumumab (D2) in subjects with relapsed and refractory multiple myeloma. This study will also explore ...

Diagnosis: Multiple Myeloma

Phase: 1 / 2

Protocol Number: 16-516

ACE-011 With Lenalidomide+Dexamethasone for Relapsed/Refractory Multiple Myeloma

It is possible that the combination of lenalidomide, dexamethasone and ACE 011 may reduce or prevent the growth of cancer cells along with improving anemia and bone lesions that sometimes occur in ...

Diagnosis: Multiple Myeloma

Phase: 1

Protocol Number: 11-318

A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma

First in human, open-label, sequential dose escalation and expansion study of CPI-0610 in patients with progressive lymphoma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-termina...

Diagnosis: Multiple Myeloma

Phase: 1

Protocol Number: 13-348

A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma

Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated multiple myeloma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal...

Diagnosis: Multiple Myeloma

Phase: 1

Protocol Number: 13-581

Study of bb2121 in Multiple Myeloma

Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).

Diagnosis: Multiple Myeloma

Phase: 1

Protocol Number: 16-054

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

This is a multicenter, multicountry, open-label, Phase 1b study for dose finding as well as parallel cohort dose expansion(s) to determine the recommended dose and regimen of durvalumab either as m...

Diagnosis: Multiple Myeloma

Phase: 1

Protocol Number: 16-221

A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma

This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: - Lenalidomide - Durvalumab - ...

Diagnosis: Multiple Myeloma

Phase: 1

Protocol Number: 16-237

A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenalidomide and low-dose dexamethasone in participants with refractory or relapsed and refractory Multiple Myeloma (rrMM),...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 14-201

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and lymphomas that express B cell ma...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 14-456

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 15-446

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

This randomized phase II trial studies how well lenalidomide alone compared to lenalidomide, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that remains (residu...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 15-407

AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma.

At least one dose level of AMG 176 will achieve acceptable safety and tolerability in subjects with relapsed or refractory multiple myeloma

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 15-522

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Dir...

Diagnosis: Solid Tumor/Phase I, Multiple Myeloma, Lymphoma

Phase:

Protocol Number: 16-406

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)

This is a non-randomized, open-label study evaluating the safety and efficacy of pembrolizumab (MK-3475) used in combination with dinaciclib (MK-7965) in the treatment of relapsed or refractory chr...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 16-253

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1 will be an open-label, dose finding, multicenter study of ibrutinib in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma. Phase 2b will b...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 16-427

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: - Trametinib - Dabrafenib

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 16-352

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents ...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 16-537

'